![](/rp/kFAqShRrnkQMbH6NYLBYoJ3lq9s.png)
ASCO Publications
3 天之前 · Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.
Journal of Clinical Oncology - ASCO Publications
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.
ASCO Clinical Practice Guidelines | Journal of Clinical Oncology
Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline May 17, 2024. Mismatch Repair and Microsatellite Instability Testing for Immune Checkpoint Inhibitor Therapy: ASCO Endorsement of College of American Pathologists Guideline January 5, 2023. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion February 17, 2022
Journal of Clinical Oncology: Vol 43, No 4 - ASCO Publications
Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial
ASCO Daily News
The phase 3 STARTER-NET trial found that everolimus plus lanreotide more than doubles progression-free survival among patients with aggressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) versus everolimus therapy alone, and …
Frontline mRCC Treatment in 2025: Translating Long-Term Data …
2025年1月30日 · The treatment landscape for metastatic renal cell carcinoma has undergone a fundamental transformation since 2018, transitioning from VEGF-targeted monotherapy to immunotherapy-based combinations. Current treatment decisions are centered on dual immunotherapy (nivolumab plus ipilimumab) or immunotherapy plus VEGF inhibitor combinations. However, long-term data have revealed important nuances ...
About ASCO Journals - ASCO Publications
JCO Global Oncology. JCO Global Oncology (JCO GO) is an online only, open access journal focused on cancer care, research and care delivery issues unique to countries and settings with limited healthcare resources.JCO GO aims to provide a home for high-quality literature that fulfills a growing need for content describing the array of …
Journal of Clinical Oncology: Vol 43, No 5 - ASCO Publications
2024年11月14日 · American Society of Clinical Oncology. 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2025 American Society of Clinical Oncology
Adapting the CRC Treatment Landscape to Address the Rise in …
2025年1月29日 · Early-onset colorectal cancer (CRC), or CRC diagnosed before age 50, now accounts for approximately 10% of all CRCs. These patients face a variety of unique challenges and complex needs, including delayed diagnosis, financial toxicity, and concerns related to fertility and mental health—all contributing to a lower quality of …
JCO Global Oncology - ASCO Publications
2025年1月30日 · Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy.